Percutaneous Coronary RevascularizationHCR registryNCT03788369
Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization
An observational study of Percutaneous Coronary Revascularization and Coronary Stenosis, run by Seung-Jung Park at 1 site in South Korea.
Trial summary
This study evaluated the effectiveness and safety of Hybrid Coronary Revascularization in real-world practice. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Percutaneous Coronary Revascularization, Coronary Stenosis, Coronary Artery Disease Progression
- What is being tested?
- Hybrid Coronary Revascularization
- Type of treatment
- Surgery or procedure
- How many people
- 6 participants
- Where
- 1 siteSouth Korea
- Study dates
- 5 Apr 2019to 13 Apr 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with hybrid coronary revascularization due to multivessel coronary artery disease(must include left anterior descending artery)
Who may be able to join
- Age 20 and more
- Hybrid coronary revascularization due to multivessel coronary artery disease(must include left anterior descending artery)
- Written consent
Who cannot join
- Previous CABG(coronary artery bypass graft)
- Life expectancy ≤1 year
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization, a Non-randomized, Prospective, Open-label Registry in Real-world Practice
This study evaluated the effectiveness and safety of Hybrid Coronary Revascularization in real-world practice.
- Conditions
- Percutaneous Coronary Revascularization, Coronary Stenosis, Coronary Artery Disease Progression, Coronary Artery Bypass Grafting
- Being tested
- Hybrid Coronary Revascularization
- Keywords
- Hybrid coronary revascularization
- Medical subject headings
- Coronary Stenosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hybrid Coronary RevascularizationProcedure or surgery
Also called HCR
Hybrid coronary revascularization (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior descending artery with percutaneous coronary intervention (PCI) of non-left anterior descending vessels.
| Study group | Role | What they receive |
|---|---|---|
| Multivessel coronary artery disease | must include left anterior descending artery Receives: Procedure: Hybrid Coronary Revascularization |
What is being measured
The primary outcome is the main question the study is designed to answer.
a composite event of death, myocardial infarction, TVR(Target Vessel Revascularization), or stroke.
Patients who have experienced any one of the following events are considered to have experienced the composite outcome: death, myocardial infarction, TVR(Target Vessel Revascularization), or stroke.
Measured: 5 years
Secondary outcomes (10)
All death
Measured: 5 years
Cardiac death
Measured: 5 years
Myocardial infarction
Measured: 5 years
a composite event of all death or myocardial infarction
Measured: 5 years
a composite event of cardiac death or myocardial infarction
Measured: 5 years
TVR(Target Vessel Revascularization)
Measured: 5 years
TLR(Target Lesion Revascularization)
Measured: 5 years
Stent thrombosis
by an Academic Research Consortium (ARC) category
Measured: 5 years
Cerebrovascular event
Measured: 5 years
Procedural success
Procedural success is defined as < 30% final stenosis and the absence of in-hospital event including death, Q-wave myocardial infarction or urgent repeat revascularization.
Measured: 5 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Dec 2018
- Study start5 Apr 2019
- Primary completion13 Apr 2026
- Study completion13 Apr 2026
Why it stopped: Early termination due to low enrollment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Percutaneous Coronary RevascularizationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 6 participants (actual)
Sponsor and investigators
- Lead sponsor
- Seung-Jung Park
- Sponsor type
- University, hospital or other
- Collaborators
- CardioVascular Research Foundation, Korea
- Responsible party
- Sponsor-investigator, Seung-Jung Park, Asan Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03788369
- Sponsor's protocol ID
- AMCCV2018-12
- Acronym
- HCR registry
- Status last verified
- Apr 2026
- First submitted
- 21 Dec 2018
- Last updated
- 15 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 15 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization, a Non-randomized, Prospective, Open-label Registry in Real-world Practice
- ClinicalTrials.gov ID
- NCT03788369
- Acronym / sponsor ID
- HCR registry / AMCCV2018-12
- Conditions
- Percutaneous Coronary Revascularization, Coronary Stenosis, Coronary Artery Disease Progression, Coronary Artery Bypass Grafting
- Keywords
- Hybrid coronary revascularization
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Early termination due to low enrollment
- Enrolment
- 6 participants (actual)
- Lead sponsor
- Seung-Jung ParkUniversity, hospital or other
- Collaborators
- CardioVascular Research Foundation, Korea
- Study start
- 5 Apr 2019 (actual)
- Primary completion
- 13 Apr 2026 (actual)
- Study completion
- 13 Apr 2026 (actual)
- First posted
- 27 Dec 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluated the effectiveness and safety of Hybrid Coronary Revascularization in real-world practice.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Multivessel coronary artery disease | – | Procedure: Hybrid Coronary Revascularizationmust include left anterior descending artery |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with hybrid coronary revascularization due to multivessel coronary artery disease(must include left anterior descending artery)
Key inclusion criteria (3 listed)
- Age 20 and more
- Hybrid coronary revascularization due to multivessel coronary artery disease(must include left anterior descending artery)
- Written consent
Key exclusion criteria (2 listed)
- Previous CABG(coronary artery bypass graft)
- Life expectancy ≤1 year
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hybrid Coronary RevascularizationAlso: HCRHybrid coronary revascularization (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior descending artery with percutaneous coronary intervention (PCI) of non-left anterior descending vessels. | Procedure or surgery | Multivessel coronary artery disease |
Primary outcome
a composite event of death, myocardial infarction, TVR(Target Vessel Revascularization), or stroke.
Time frame: 5 years
Patients who have experienced any one of the following events are considered to have experienced the composite outcome: death, myocardial infarction, TVR(Target Vessel Revascularization), or stroke.
10 secondary outcomes
All death
Time frame: 5 years
Cardiac death
Time frame: 5 years
Myocardial infarction
Time frame: 5 years
a composite event of all death or myocardial infarction
Time frame: 5 years
a composite event of cardiac death or myocardial infarction
Time frame: 5 years
TVR(Target Vessel Revascularization)
Time frame: 5 years
TLR(Target Lesion Revascularization)
Time frame: 5 years
Stent thrombosis
Time frame: 5 years
Cerebrovascular event
Time frame: 5 years
Procedural success
Time frame: 5 days
Results and safety
The study was stopped early (reason given: Early termination due to low enrollment). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Percutaneous Coronary Revascularization
Not yet recruiting
Hs-CRP-Guided Colchicine Treatment Targets in Very-High-Risk Patients With Coronary Artery Disease After PCI (TARGET-CHD)
Coronary Artery Disease, Atherosclerotic Cardiovascular Disease (ASCVD)
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Not yet recruiting
ADVA ACE Coronary Stent System in Coronary Artery Disease Patients (ADVANCE)
Coronary Artery Disease, De Novo Stenosis Lesion
Recruiting
Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors
RecruitingPhase 3
Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI
Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Percutaneous Coronary Revascularization and Coronary Stenosis, run by Seung-Jung Park at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 15 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Early termination due to low enrollment). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
a composite event of death, myocardial infarction, TVR(Target Vessel Revascularization), or stroke. (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2026.